StemCell Institute Inc. (TYO:7096)
Japan
· Delayed Price · Currency is JPY 1,281.00
-24.00 (-1.84%)
May 12, 2025, 3:30 PM JST
StemCell Institute Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2018 - 2019 |
| Revenue | 2,637 | 2,481 | 2,091 | 1,781 | 1,409 | 1,676 | Upgrade
|
| Revenue Growth (YoY) | 10.06% | 18.65% | 17.41% | 26.40% | -15.93% | 45.87% | Upgrade
|
| Cost of Revenue | 977 | 905 | 755 | 670 | 485 | 543 | Upgrade
|
| Gross Profit | 1,660 | 1,576 | 1,336 | 1,111 | 924 | 1,133 | Upgrade
|
| Selling, General & Admin | 1,223 | 1,142 | 1,024 | 874 | 829 | 750 | Upgrade
|
| Operating Expenses | 1,243 | 1,162 | 1,038 | 884 | 837 | 750 | Upgrade
|
| Operating Income | 417 | 414 | 298 | 227 | 87 | 383 | Upgrade
|
| Interest & Investment Income | 6 | 3 | 1 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 3 | -1 | - | -16 | 4 | -1 | Upgrade
|
| EBT Excluding Unusual Items | 426 | 416 | 299 | 211 | 91 | 382 | Upgrade
|
| Gain (Loss) on Sale of Investments | 136 | 22 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | 2 | -21 | - | - | - | Upgrade
|
| Pretax Income | 562 | 440 | 278 | 211 | 91 | 382 | Upgrade
|
| Income Tax Expense | 167 | 130 | 80 | 78 | 29 | 105 | Upgrade
|
| Net Income | 395 | 310 | 198 | 133 | 62 | 277 | Upgrade
|
| Net Income to Common | 395 | 310 | 198 | 133 | 62 | 277 | Upgrade
|
| Net Income Growth | 41.07% | 56.57% | 48.87% | 114.52% | -77.62% | 95.07% | Upgrade
|
| Shares Outstanding (Basic) | 10 | 10 | 10 | 5 | 5 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 10 | 10 | 5 | 5 | 5 | Upgrade
|
| Shares Change (YoY) | -27.27% | - | 102.33% | 4.05% | - | - | Upgrade
|
| EPS (Basic) | 38.55 | 30.25 | 19.32 | 26.26 | 12.74 | 56.91 | Upgrade
|
| EPS (Diluted) | 38.55 | 30.25 | 19.32 | 26.26 | 12.74 | 56.91 | Upgrade
|
| EPS Growth | 93.97% | 56.57% | -26.42% | 106.16% | -77.62% | 95.07% | Upgrade
|
| Free Cash Flow | - | 151 | 43 | 288 | -164 | - | Upgrade
|
| Free Cash Flow Per Share | - | 14.74 | 4.20 | 56.87 | -33.70 | - | Upgrade
|
| Gross Margin | 62.95% | 63.52% | 63.89% | 62.38% | 65.58% | 67.60% | Upgrade
|
| Operating Margin | 15.81% | 16.69% | 14.25% | 12.75% | 6.17% | 22.85% | Upgrade
|
| Profit Margin | 14.98% | 12.50% | 9.47% | 7.47% | 4.40% | 16.53% | Upgrade
|
| Free Cash Flow Margin | - | 6.09% | 2.06% | 16.17% | -11.64% | - | Upgrade
|
| EBITDA | 549 | 534 | 402 | 323 | 119 | - | Upgrade
|
| EBITDA Margin | 20.82% | 21.52% | 19.23% | 18.14% | 8.45% | - | Upgrade
|
| D&A For EBITDA | 132 | 120 | 104 | 96 | 32 | - | Upgrade
|
| EBIT | 417 | 414 | 298 | 227 | 87 | 383 | Upgrade
|
| EBIT Margin | 15.81% | 16.69% | 14.25% | 12.75% | 6.17% | 22.85% | Upgrade
|
| Effective Tax Rate | 29.72% | 29.54% | 28.78% | 36.97% | 31.87% | 27.49% | Upgrade
|
| Advertising Expenses | - | 196 | 194 | 175 | 166 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.